lacosamide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 59 Diseases   24 Trials   24 Trials   1999 News 


«12...14151617181920212223242526»
  • ||||||||||  lacosamide / generics
    Journal:  Mutations in SCN3A cause early infantile epileptic encephalopathy. (Pubmed Central) -  Aug 3, 2019   
    These findings establish SCN3A as a new gene for infantile epileptic encephalopathy and suggest a potential pharmacologic intervention. These findings also reinforce the role of Nav1.3 as an important regulator of neuronal excitability in the developing brain while providing additional insight into mechanisms of slow inactivation of Nav1.3.
  • ||||||||||  Fycompa (perampanel) / Eisai
    Journal:  Seizures and Anticonvulsants in Brain Tumours: Frequency, Mechanisms and Anti-Epileptic Management. (Pubmed Central) -  Aug 1, 2019   
    ...Levetiracetam followed by lacosamide or valproic acid are the agents of choice...Lamotrigine, perampanel, zonisamide or clobazam are other good choices...Plasma monitoring of AEDs for detecting drug insufficiency, interactions or toxicity helps in choosing the proper dose regimen. For practical use, tables on drug interactions between AEDs and cancer therapy are added together with a guideline on the medical management of seizure control including dose regimens.
  • ||||||||||  lacosamide / generics
    Clinical, Journal, HEOR:  Lacosamide as first-line treatment option in focal epilepsy: a cost-utility analysis for the Greek healthcare system. (Pubmed Central) -  Aug 1, 2019   
    For practical use, tables on drug interactions between AEDs and cancer therapy are added together with a guideline on the medical management of seizure control including dose regimens. Lacosamide is a cost-effective option at a willingness-to-pay threshold of €30,000 per QALY, representing a valuable monotherapy treatment option for patients with focal epileptic seizures in the Greek setting.
  • ||||||||||  Briviact (brivaracetam) / UCB
    Journal:  Recent anti-seizure medications in the intensive care unit. (Pubmed Central) -  Jul 26, 2019   
    Recent ASMs and could represent better treatment choices in critically ill patients than older ones but this needs to be confirmed in randomized controlled studies. In general, further studies are required to clarify the indications and optimal use of ASMs in the critical care setting.
  • ||||||||||  dalfampridine / generics, carbamazepine / generics
    Preclinical, Journal:  The 4-Aminopyridine Model of Acute Seizures in vitro Elucidates Efficacy of New Antiepileptic Drugs. (Pubmed Central) -  Jul 19, 2019   
    ...Previous studies have shown that the 4-AP model is capable to recapitulate the antiepileptic efficacy of standard antiepileptic drugs (AEDs) such as valproate or carbamazepine...Specifically, levetiracetam reduced SLE frequency while lacosamide and zonisamide at higher doses completely blocked SLE incidence...Further studies with negative controls, e.g., penicillin as a proconvulsant, and other clinically relevant AEDs are needed to determine if this acute in vitro model might be useful as exploratory screening tool. In view of the increasing sensitivity toward animal welfare, an affective in vitro model may help to reduce the number of laboratory animals deployed in burdening in vivo experiments and to preselect substances for subsequent testing in time- and cost-laborious models of chronic epilepsy.
  • ||||||||||  lacosamide / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date:  ASPIRE: Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children. (clinicaltrials.gov) -  Jul 18, 2019   
    P2/3,  N=103, Completed, 
    In view of the increasing sensitivity toward animal welfare, an affective in vitro model may help to reduce the number of laboratory animals deployed in burdening in vivo experiments and to preselect substances for subsequent testing in time- and cost-laborious models of chronic epilepsy. Recruiting --> Completed | Trial completion date: Jun 2020 --> Jun 2019 | Trial primary completion date: Jun 2020 --> Jun 2019
  • ||||||||||  lacosamide / generics
    Clinical, Journal:  Lacosamide on background eeg activity in brain tumor-related epilepsy patients: A case series study. (Pubmed Central) -  Jul 17, 2019   
    This is the first study that evaluates the effect of LCM on background EEG activity, using qEEG in BTRE patients. Future research in this area could include prospective studies with qEEG for a longer follow-up period to assess the impact of AEDs on brain functions in this particular fragile patient population.
  • ||||||||||  pregabalin / generics
    Review, Journal:  Management of brain tumor-related epilepsy. (Pubmed Central) -  Jul 13, 2019   
    Data for this review article were compiled by searching for scholarly articles using the following keywords: brain tumor, epilepsy, seizure, tumor-related epilepsy, central nervous system, epidemiology, review, clinical trial, and surgery. Articles were screened for relevance by title and abstract, and selected for review and inclusion based on significant contribution to the topics discussed.
  • ||||||||||  Fycompa (perampanel) / Eisai, Briviact (brivaracetam) / UCB, Aptiom (eslicarbazepine) / Sumitomo Dainippon, Eisai
    Journal:  Safety profile of the newest antiepileptic drugs: a curated literature review. (Pubmed Central) -  Jul 11, 2019   
    Articles were screened for relevance by title and abstract, and selected for review and inclusion based on significant contribution to the topics discussed. Early detection of ADRs could lead to an improvement in patients' quality of life, therefore it is important to monitor ADRs and to adequately perform post marketing surveillance in the clinical practice setting.
  • ||||||||||  lacosamide / generics, carbamazepine / generics
    Clinical, Journal:  Lacosamide: A Review in Focal-Onset Seizures in Patients with Epilepsy. (Pubmed Central) -  Jun 20, 2019   
    Oral lacosamide was generally well tolerated over the short- and longer-term when administered as adjunctive therapy, a conversion to monotherapy agent and monotherapy in adults and adolescents and when administered as adjunctive therapy in children aged ≥ 4 years. Thus, lacosamide is a useful option for the management of focal-onset seizures across a broad age range, starting as early as 4 years of age.
  • ||||||||||  lacosamide / generics
    Journal:  Absence status induced by lacosamide adjunctive therapy. (Pubmed Central) -  Jun 19, 2019   
    The absence status was successfully broken by lorazepam, and lacosamide was discontinued. The patient had no further confusional episodes at the most recent follow-up visit, four months after discharge.
  • ||||||||||  lacosamide / generics, levetiracetam / generics
    Clinical, Journal:  Tonic status epilepticus in a centenarian woman. (Pubmed Central) -  Jun 19, 2019   
    Our case indicates a potential therapeutic effect of lacosamide on TSE in the elderly after treatment failure with first-line anti-seizure drugs. [Published with video sequence on www.epilepticdisorders.com].
  • ||||||||||  lacosamide / generics
    Clinical, Journal:  Pain relief in a neuropathy patient by lacosamide: Proof of principle of clinical translation from patient-specific iPS cell-derived nociceptors. (Pubmed Central) -  Jun 15, 2019   
    Nevertheless, we will require further well-designed randomised controlled clinical trials including large samples of patients eligible for PC to draft a consensus document recommending adequate, rational, and effective use of AEDs, based on a high level of evidence, in this highly complex area of medical care. Thus, we are here presenting one example of successful patient specific precision medicine using iPSC technology and individualized therapeutic treatment based on patient-derived sensory neurons.
  • ||||||||||  lacosamide / generics
    Journal:  Therapeutic Drug Monitoring of Lacosamide by LC-MS/MS. (Pubmed Central) -  Jun 7, 2019   
    A deuterated internal standard is used to correct for any loss of analyte during the process of extraction and analysis. A seven-point calibration curve and two levels of quality controls are included in each batch.
  • ||||||||||  lacosamide / generics
    Clinical, Journal:  Modeling and simulation for the evaluation of dose adaptation rules of intravenous lacosamide in children. (Pubmed Central) -  Jun 7, 2019   
    Plasma clearance was scaled using a fixed allometric exponent on body weight, while central volume of distribution used a freely estimated allometric exponent. The model-based pharmacokinetic predictions suggested that there is no need to adapt the recommendations regarding intravenous infusion durations in children compared with adults.
  • ||||||||||  Rituxan (rituximab) / Roche, Biogen
    Journal:  Morvan's syndrome treated successfully with rituximab and lacosamide. (Pubmed Central) -  May 30, 2019   
    The clinical course resembled that of anti-NMDA receptor encephalitis, where patients often recover surprisingly well despite severe symptoms and an extensive time in intensive care. A possible explanation is the comparatively low levels of NfL, indicating disease processes that are not characterised by extensive neuroaxonal degeneration.
  • ||||||||||  lacosamide / generics
    Clinical, Journal:  Lacosamide in treatment of patients with focal epilepsy and comorbid mental disorders (Pubmed Central) -  May 22, 2019   
    Clinical-psychopathological and experimental-psychological monitoring of patients' condition over time was carried out using the Mental Health Comprehensive Assessment Scale (MHCAS), the Global Clinical Impression scale (GCI). As a result, the majority of patients (58 people (63.7%)) achieved remission with good tolerability and positive changes in cognitive functions and emotional-volitional characteristics, confirming their stability after 1 year of LCM administration.
  • ||||||||||  lacosamide / Generic mfg.
    Enrollment open:  The Effect of Lacosamide in Peripheral Neuropathic Pain (clinicaltrials.gov) -  May 21, 2019   
    P2,  N=108, Recruiting, 
    As a result, the majority of patients (58 people (63.7%)) achieved remission with good tolerability and positive changes in cognitive functions and emotional-volitional characteristics, confirming their stability after 1 year of LCM administration. Not yet recruiting --> Recruiting
  • ||||||||||  Trial completion date, Trial primary completion date:  PADRE: Pharmacokinetics of Antiepileptics in Patients on CRRT (clinicaltrials.gov) -  May 20, 2019   
    P4,  N=30, Recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Jun 2019 --> Dec 2019 | Trial primary completion date: Mar 2019 --> Dec 2019
  • ||||||||||  Seizalam (midazolam intramuscular) / Pfizer
    Review, Journal:  Focal status epilepticus: a review of pharmacological treatment. (Pubmed Central) -  May 12, 2019   
    The available scientific evidence is insufficient to claim that pharmacological treatment of focal SE should be different from treatment for generalised SE. More studies with a greater number of patients are needed.